Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Study Identifier:
381-201-00020
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
EU CT ID:
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information:
Will Be Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: VIS954
- Drug: Standard Of Care (SOC)
- Drug: Placebo
Date
Dec 2026 - Nov 2029
Phase 1/2
Phase 2/3
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Inclusion and Exclusion Criteria
- Key Inclusion Criteria
- Participant must be at least 18 years of age or have reached the legal age of consent in their country, whichever is higher.
- Participant must have a new diagnosis or a relapse of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), specifically granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
- Participant must have evidence of ANCA antibodies (anti-myeloperoxidase \[MPO\] or anti-proteinase 3 \[PR3\]) associated with AAV.
- Participant must have active AAV with new or worsening signs or symptoms documented, as demonstrated by established disease activity criteria.
- Key Exclusion Criteria
- Participant must not require advanced organ support for severe disease at screening.
- Participant must not have a life-threatening illness requiring intensive care at screening.
- Participant must not have another autoimmune disease that could affect evaluation of the study treatment, such as eosinophilic granulomatosis with polyangiitis (EGPA), systemic lupus erythematosus (lupus), IgA vasculitis, rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane (anti-GBM) disease, cryoglobulinemic vasculitis, or suspected drug-induced AAV.
- Participant must not have received certain immune-modifying treatments within 6 months before screening, including avacopan, B-cell-targeted therapies, chimeric antigen receptor T-cell (CAR-T) cell therapies, belimumab, tocilizumab, or similar biologic therapies that affect the immune system.
- Participant must not be receiving azathioprine, mycophenolate mofetil, or methotrexate unless they are willing and able to stop these medications before starting study treatment.
- Participant must not have received rituximab, cyclophosphamide, or another B-cell-depleting therapy within 6 months before screening, except when rituximab or cyclophosphamide was administered as part of standard-of-care treatment.
Protocol Summary
This is a phase 2, double-blind, randomized, controlled, multicenter trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of 2 VIS954 dosing regimens in patients with moderate to severe acute anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).
Study Locations
No locations found.
© 2025 Otsuka America Pharmaceutical,
Inc All rights reserved.
July 2025 01US25EUC0279
Requirements information
- Key Inclusion Criteria
- Participant must be at least 18 years of age or have reached the legal age of consent in their country, whichever is higher.
- Participant must have a new diagnosis or a relapse of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), specifically granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
- Participant must have evidence of ANCA antibodies (anti-myeloperoxidase \[MPO\] or anti-proteinase 3 \[PR3\]) associated with AAV.
- Participant must have active AAV with new or worsening signs or symptoms documented, as demonstrated by established disease activity criteria.
- Key Exclusion Criteria
- Participant must not require advanced organ support for severe disease at screening.
- Participant must not have a life-threatening illness requiring intensive care at screening.
- Participant must not have another autoimmune disease that could affect evaluation of the study treatment, such as eosinophilic granulomatosis with polyangiitis (EGPA), systemic lupus erythematosus (lupus), IgA vasculitis, rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane (anti-GBM) disease, cryoglobulinemic vasculitis, or suspected drug-induced AAV.
- Participant must not have received certain immune-modifying treatments within 6 months before screening, including avacopan, B-cell-targeted therapies, chimeric antigen receptor T-cell (CAR-T) cell therapies, belimumab, tocilizumab, or similar biologic therapies that affect the immune system.
- Participant must not be receiving azathioprine, mycophenolate mofetil, or methotrexate unless they are willing and able to stop these medications before starting study treatment.
- Participant must not have received rituximab, cyclophosphamide, or another B-cell-depleting therapy within 6 months before screening, except when rituximab or cyclophosphamide was administered as part of standard-of-care treatment.